IFP Advisors
MLTX icon

IFP Advisors’s MoonLake Immunotherapeutics MLTX Stock Holding History

IFP Advisors’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.66K Buy
398
+297
+294% +$4.85K ﹤0.01% 3861
2026
Q2 		$1.97K Buy
+101
New +$1.83K ﹤0.01% 4240
2026
Q1 		– Sell
-1
Closed -$13 – 5102
2025
Q4 		$13 Sell
1
-1,100
-100% -$13K ﹤0.01% 4830
2025
Q3 		$7.89K Buy
1,101
+1,084
+6,376% +$56.5K ﹤0.01% 3026
2025
Q2 		$802 Buy
+17
New +$693 ﹤0.01% 4291
2024
Q4 		– Hold
0
– – – 4238

Other funds holding MLTX

Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
BWM
BankPlus Wealth Management Jackson, Mississippi $229M AUM 13.58% 1-Year Est. Return
BC
Bulwark Capital Fernandina Beach, Florida $189M AUM 7.81% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $32B AUM 32.86% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

IFP Advisors's MLTX Position: Q3 2026 in Review

IFP Advisors increased its MoonLake Immunotherapeutics (MLTX) stake by 294% in Q3 2026, buying an estimated $4.85K and bringing the position to 398 shares worth $4.66K. The position accounts for ﹤0.01% of the portfolio, ranked #3861.

IFP Advisors first reported a position in MLTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $7.89K in Q3 2025. 9 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

  • IFP Advisors held 398 shares of MoonLake Immunotherapeutics worth $4.66K as of Q3 2026.
  • IFP Advisors bought 297 MoonLake Immunotherapeutics shares in Q3 2026, an estimated $4.85K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #3861 holding.
  • IFP Advisors first reported a position in MoonLake Immunotherapeutics in Q2 2025 and has held it in 5 quarters since.
  • IFP Advisors's MoonLake Immunotherapeutics position peaked at $7.89K in Q3 2025.
  • 9 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.